Dohlman Henrik G
From the Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, North Carolina 27599-7260
J Biol Chem. 2015 Aug 7;290(32):19469-70. doi: 10.1074/jbc.R115.675728. Epub 2015 Jun 30.
Over the past half-century, The Journal of Biological Chemistry has been the venue for many landmark publications on the topic of G protein-coupled receptors (GPCRs, also known as seven-transmembrane receptors). The GPCR superfamily in humans is composed of about 800 members, and is the target of about one-third of all pharmaceuticals. Most of these drugs target a very small subset of GPCRs, and do so by mimicking or competing with endogenous hormones and neurotransmitters. This thematic minireview series examines some emerging trends in GPCR drug discovery. The first article describes efforts to systematically interrogate the human "GPCR-ome," including more than 150 uncharacterized "orphan" receptors. The second article describes recent efforts to target alternative receptor binding sites with drugs that act as allosteric modulators of orthosteric ligands. The third article describes how the recent expansion of GPCR structures is providing new opportunities for computer-guided drug discovery. Collectively, these three articles provide a roadmap for the most important emerging trends in GPCR pharmacology.
在过去的半个世纪里,《生物化学杂志》一直是发表许多关于G蛋白偶联受体(GPCRs,也称为七跨膜受体)这一主题的里程碑式论文的平台。人类的GPCR超家族由大约800个成员组成,并且是所有药物中约三分之一的靶点。这些药物中的大多数作用于GPCRs的一个非常小的子集,并且是通过模拟或与内源性激素和神经递质竞争来实现的。这个主题迷你综述系列探讨了GPCR药物发现中的一些新趋势。第一篇文章描述了系统研究人类“GPCR组”的努力,其中包括150多个未被表征的“孤儿”受体。第二篇文章描述了最近利用作为正构配体变构调节剂的药物靶向替代受体结合位点的努力。第三篇文章描述了GPCR结构最近的扩展如何为计算机辅助药物发现提供新机会。这三篇文章共同为GPCR药理学中最重要的新趋势提供了路线图。